News
38m
Stockhead on MSNNeurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
The onset of motor neurone disease (MND) left Sarah without a voice and the use of her hands at the age of 34. It was within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results